A drug-coated balloon beat conventional balloon angioplasty in treating high-risk patients with in-stent restenosis for outcomes of target lesion restenosis or failure, the AGENT IDE study has shown.
Study identifies a new potential target for treating vascular disease webwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webwire.com Daily Mail and Mail on Sunday newspapers.
Vascular diseases, including myocardial infarction, stroke, renal failure, and peripheral vascular disease, continue to account for one third of all mortality in the United States, Europe, and the developing world (World Health Organization, 2021). Vascular smooth muscle cell (VSMC) activation plays a crucial role in the development of multiple vascular diseases. In a novel study in The American Journal of Pathology, published by Elsevier, researchers found that when fragile-X related protein-1 (FXR1) is absent, VSMC proliferate more slowly, become senescent, and scar tissue (neointima) development is reduced. Therefore, drugs targeting FXR1 may treat vascular proliferative diseases.
One complaint alleges the interventional cardiologist performed 44 heart catheterizations and inserted at least 41 stents into one patient, according to an investigation by a local news outlet.
Mean session time was 153 min when both procedures were included. They were performed safely and successfully and could be recommended at the same session even after the pandemic, researchers say.